Loading
A phase 1/2 trial of Capecitabine in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. is a phase 1/2 interventional study registered as NCT06247995 by Novartis Pharmaceuticals, with 20 participants enrolled, started 2024-08-14 and due to reach its primary completion in 2027-04-14. Interventions recorded: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB and Capecitabine.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.